COMPARISON

Insulin degludec vs Sermorelin

5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.

Answer

Insulin degludec is authorised or registered in 10 and Sermorelin in 0 of the 10 registers read. Insulin degludec: highest phase Phase 4 (after approval). Sermorelin: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

Insulin degludecSermorelin
Registered trials
differs
255
clinicaltrials.gov · 2026-10-03
27
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: Xultophy 100/3.6
openfda · 2026-10-03T17:23:44.062Z
Not checked
no record of "fdaLabel" for sermorelin
EU authorisation
differs
Authorised
ema · 2026-10-03
Nothing on record
ema read 2026-08-31
EU authorised on
differs
2013-01-20
ema · 2026-10-03
Not checked
no record of "authorisedOn" for sermorelin
ATC code
differs
A10AE06
ema · 2026-10-03
Not checked
no record of "atcCode" for sermorelin

LEGAL STATUS

Approval in each country read

CountryInsulin degludecSermorelinRegister
United StatesFDA-approvedNot on the registerRegulator FDA
European UnionAuthorisedNot on the registerRegulator EMA
United KingdomAuthorisedNot on the registerRegulator MHRA
CanadaAuthorisedNot on the registerRegulator Health Canada
AustraliaRegisteredStatus unknownRegulator TGA
SwitzerlandAuthorisedNot on the registerRegulator Swissmedic
BrazilRegistadoNot on the registerRegulator ANVISA
SerbiaAuthorisedNot on the registerRegulator ALIMS
SingaporeRegisteredNot on the registerRegulator HSA
TurkeyRuhsatliNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.